Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from InMed Pharmaceuticals ( (INM) ) is now available.
InMed Pharmaceuticals held a special meeting on June 13, 2025, to approve a potential issuance of more than 20% of its common shares, as per Nasdaq rules. However, due to the lack of a quorum, no business was conducted, and the board is considering whether to reschedule the meeting or address the proposal at the annual general meeting.
Spark’s Take on INM Stock
According to Spark, TipRanks’ AI Analyst, INM is a Neutral.
InMed Pharmaceuticals shows significant financial challenges with persistent losses and negative cash flows, which heavily weigh down its score. The stock’s technical indicators reflect short-term positive momentum, offering some optimism amid volatility. The valuation remains constrained by ongoing losses and lack of profitability metrics, typical for the biotechnology sector.
To see Spark’s full report on INM stock, click here.
More about InMed Pharmaceuticals
Average Trading Volume: 1,321,589
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.08M
For a thorough assessment of INM stock, go to TipRanks’ Stock Analysis page.